Identificación molecular y perfil de sensibilidad antifúngica de Candida albicans y Candida dubliniensis aisladas de pacientes ambulatorios y hospitalizados
DOI:
https://doi.org/10.52379/mcs.v8i3.431Keywords:
Candida albicans, Candida dubliniensis, Polymerase Chain Reaction, Microbial Susceptibility Tests, Antifungal AgentsAbstract
Introduction: C. albicans together with C. dubliniensis and C. Africana, form the Candida albicans Complex. These species are closely related to each other, making differentiation by conventional methods difficult. Objectives: To differentiate Candida albicans and Candida dubliniensis by molecular method in isolates from outpatients and hospitalized patients from Central, Paraguay and to know their susceptibility profile. Methods: Yeasts isolated from respiratory materials, oral cavity, purulent secretions, blood, urine and others were included. An end-point duplex PCR was performed on the isolates that developed greenish coloration in chromogenic medium (CONDA®, Spain). DNA was extracted using the Wizard® Genomic DNA Kit (Promega, USA) with some modifications. Antifungal susceptibility was determined by VITEK® 2 to a subgroup of isolates. Results: Of 1065 isolates, 838 (78,7 %) were C. albicans and 3 (0,3 %) C. dubliniensis, the latter coming from the oral cavity; the remaining 224 were negative for both species. 94,4 % of 503 C. albicans isolates were susceptible to fluconazole, 97,6 % to voriconazole, 99,4 % to amphotericin B, 100 % to caspofungin and micafungin. The three isolates of C. dubliniensis presented MICs of ? 0,5 µg/mL against fluconazole, ? 0,12 µg/mL against voriconazole and ? 0,25 µg/mL against amphotericin B. Conclusions: The frequency of C. dubliniensis is low compared to other studies that report values ??of 1,5 to 32 %. These isolates did not exhibit signs of resistance. C. albicans exhibited good susceptibility to antifungals tested.
Downloads
References
Arriola A, Arbo A. Factores de riesgo potenciales en infecciones sistémicas por Candida spp. Rev Inst Med Trop. 2020;15(2):5-12. https://doi.org/10.18004/imt/2020.15.2.5
Suárez Álvarez P, Llanos González I, Montoya Ojeda R, Puello Hoyos M, Young Castro G, Reyes Ramos N. Colonización por Candida spp. en sujetos diabéticos y no diabéticos. Rev cuba endocrinol. 2016;27(1):59-68. URL.
Turner SA, Butler G. The Candida Pathogenic Species Complex. Cold Spring Harb Perspect Med. 2014;4(9):a01977. https://doi.org/10.1101/cshperspect.a019778
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers 2018;4:18026. https://doi.org/10.1038/nrdp.2018.26
Arastehfar A, Fang W, Pan W, Liao W, Yan L, Boekhout T. Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR. BMC Infectious Diseases. 2018;18(1):480. https://doi.org/10.1186/s12879-018-3381-5
Shokoohi G, Javidnia J, Mirhendi H, Rasekh-Jahromi A, Rezaei-Matehkolaei A, Ansari S, et al. Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single-centre experience in Iran. Mycoses. 2021;64(7):771-779. https://doi.org/10.1111/myc.13280
Gayoso B, Samudio M, Duré C, Fariña N, Alfonso L, Franco I, et al. Especies y sensibilidad a antifúngicos de cepas de Candida spp. aisladas de la cavidad bucal de pacientes con VIH de Paraguay. Mem Inst Investig Cienc Salud. 2021;19(3):12-24. https://doi.org/10.18004/mem.iics/1812-9528/2021.019.03.12
Ahmad S, Khan Z, Asadzadeh M, Theyyathel AM, Chandy RM. Performance comparison of phenotypic and molecular methods for detection and differentiation of Candida albicans and Candida dubliniensis. BMC infectious diseases. 2012;12:230. https://doi.org/10.1186/1471-2334-12-230
CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 3rd ed. CLSI supplement M27M44S. Clinical and Laboratory Standards Institute; 2022. Disponible en: https://clsi.org/
CLSI. Epidemiological Cutoff values for Antifungal Susceptibility Testing, 2nd ed. CLSI supplement M59. Clinical and Laboratory Standards Institute; 2018. Disponible en: https://clsi.org/
Xu J. Fungal DNA barcoding. Genome. 2016;59(11):913-932. https://doi.org/10.1139/gen-2016-0046
Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. PNAS. 2012;109(16):6241-6. https://doi.org/10.1073/pnas.1117018109
Al?Sweih N, Ahmad S, Khan ZU, Khan S, Chandy R. Prevalence of Candida dubliniensis among germ tube-positive Candida isolates in a maternity hospital in Kuwait. Mycoses. 2005;48(5):347-51. https://doi.org/10.1111/j.1439-0507.2005.01143.x
Ribeiro Ribeiro AL, de Alencar Menezes TO, de Melo Alves-Junior S, de Menezes SAF, Marques-da-Silva SH, Rosário Vallinoto AC. Oral carriage of Candida species in HIV-infected patients during highly active antiretroviral therapy (HAART) in Belém, Brazil. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(1):29-33. https://doi.org/10.1016/j.oooo.2015.03.008
Mariel-Carballo G. Phenotypic identification of Candida dubliniensis isolated from candidiasis of oral cavity in immunocompromised patients. Dermatología Rev Mex. 2019;63(1):14-25. URL.
Pineda G, Scollo K, Santiso G, Lehmann E, Arechavala A. Aislamiento de Candida dubliniensis en distintos materiales clínicos: Análisis de métodos fenotípicos de diferenciación con Candida albicans. Rev argent microbiol. 2008;40(4):211-217. URL.
Abharian PH, Dehghan P, Abharian PH, Tolouei S. Molecular characterization of Candida dubliniensis and Candida albicans in the oral cavity of drug abusers using duplex polymerase chain reaction. Current Medical Mycology. 2018;4(1):12. https://doi.org/10.18502/cmm.4.1.29
Khedri S, Santos A l. s., Roudbary M, Hadighi R, Falahati M, Farahyar S, et al. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Letters in Applied Microbiology. 2018;67(4):392-399. https://doi.org/10.1111/lam.13052
Mohamed H, Krema Z, Mokthar E, Ellabib M, El Magrahi H, Eshwika A. Oral Candida colonization in HIV-infected patients: Species and antifungal susceptibility in Tripoli/Libya. Int J Clin Microbiol Biochem Technol. 2018;1(1):001-8. https://doi.org/10.29328/journal.ijcmbt.1001001
Castro LÁ, Álvarez MI, Martínez E. Candida in the oral cavity of HIV-infected patients: Identification of species and susceptibility to fluconazole in Cali, Colombia. Iatreia. 2015;28(4):368-377. https://doi.org/10.17533/udea.iatreia.v28n4a02
Camacho L D, Mata E S, Pardi G, Pineda V, Roselló A, Collela MT. Evaluación de diversos métodos fenotípicos para la diferenciación entre Candida dubliniensis y Candida albicans. Kasmera. 2012;40(1):47-58. URL.
Sullivan DJ, Moran GP, Coleman DC. Candida dubliniensis: Ten years on. FEMS Microbiol Lett. 2005;253(1):9-17. https://doi.org/10.1016/j.femsle.2005.09.015
Tantivitayakul P, Panpradit N, Maudcheingka T, Klaophimai A, Lapirattanakul J. Genotyping of Candida albicans and Candida dubliniensis by 25S rDNA analysis shows association with virulence attributes in oral candidiasis. Arch Oral Biol. 2019;97:18-24. https://doi.org/10.1016/j.archoralbio.2018.10.006
Albaina O, Sahand IH, Brusca MI, Sullivan DJ, Fernandez de Larrinoa I, Moragues MD. Identification and characterization of nine atypical Candida dubliniensis clinical isolates. J. Med. Microbiol.. 2015;64(Pt_2):147-56. https://doi.org/10.1099/jmm.0.078832-0
Lockhart SR. Do Hospital Microbiology Laboratories Still Need To Distinguish Candida albicans from Candida dubliniensis? J Clin Microbiol. 2011;49(12):4415. https://doi.org/10.1128/JCM.05923-11
EUCAST. Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures. Version 4.0, 2023. The European Committee on Antimicrobial Susceptibility Testing; 2023. Disponible en: http://www.eucast.org
Zuluaga Rodríguez A, de Bedout Gómez C, Agudelo Restrepo CA, Hurtado Parra H, Arango Arteaga M, Restrepo Moreno Á, et al. Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001–2007). Rev. iberoamer. micol. 2010;27(3):125-9. https://doi.org/10.1016/j.riam.2010.04.001
Aguilar G, Araujo P, Lird G, Insaurralde S, Kawabata A, Ayala E, et al. Identificación y perfil de sensibilidad de Candida spp. aisladas de hemocultivos en hospitales de Paraguay. Rev Panam Salud Publica. 2020;44:e34. https://doi.org/10.26633/RPSP.2020.34
Ochiuzzi ME, Cataldi S, Guelfand L, Maldonado I, Arechavala A. Evaluación del sistema Vitek 2 para la identificación de las principales especies de levaduras del género Candida. Rev Argent Microbiol. 2014;46(2):107-110. https://doi.org/10.1016/S0325-7541(14)70057-4
Quiles-Melero I, García-Rodríguez J. Antifúngicos de uso sistémico. Rev Iberoam Micol. 2021;38(2):42-6. https://doi.org/10.1016/j.riam.2021.04.004
Pineda-Murillo J, Cortés-Figueroa AA, Uribarren-Berrueta T del NJ, Castañón-Olivares LR. Candidosis vaginal: Revisión de la literatura y situación de México y otros países latinoamericanos. Rev Méd Risaralda. 2017;23(1):38-44. URL.
Alburquenque C, Beltrán S, Olivares R, Falconer MA, Amaro J, Fuentes M, et al. Distribución de especies y perfil de susceptibilidad de aislados de Candida spp: la importancia de vigilar también cepas de la comunidad. Rev Chil Infectol. 2013;30(3):244-51. https://doi.org/10.4067/S0716-10182013000300002
Alcazar?Fuoli L, Mellado E. Current status of antifungal resistance and its impact on clinical practice. Br. J. Haematol. 2014;166(4):471-484. https://doi.org/10.1111/bjh.12896
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Carolina Duré, Margarita Samudio, Norma Fariña, Sonia Abente, Alicia Pereira, Rosa Guillén, Gustavo Aguilar, Belén Gayoso, Heriberto Nuñez, Desiré Almirón, Aurelia Taboada
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.